Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients
- VernacularTitle:吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价
- Author:
Xia YAN
;
Guanmin CAO
;
Daoxin WANG
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
old age;
drug therapy;
gemcitabine
- From:Journal of Third Military Medical University
2003;0(19):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate and the effects and safety of gemcitabine plus carboplatin (GEM+CBP) regimen and navebine plus cisplatin (NVB+DDP) regimens for aged patients with advanced non-small cell lung cancer (NSCLC). Methods The 60 cases of aged patients with NSCLC,over 65 years old and 35 cases beyond 70,were randomly and equally divided into 2 groups. Group A received 1 000 mg/m2 GEM at day 1 and 8,and 300 mg/m2 CBP at day 1. Group B underwent the therapy of 25 mg/ m2 NVB at day 1 and 8,and 80 mg/m2 DDP at day 1 and 3. Both were treated with 3 weeks as a cycle. Results Overall response rate was 43.3% in group A and 36.7% in group B without significant difference. The median survival time (MST) and disease median response time(DPT) was 9.2 and 4.4 months in A group,and 8.9 and 4.2 months in B group. MST,DPT and one year survival rate were similar in 2 groups. Toxicities: WHO grade Ⅲ/Ⅳ leukopenia occurred in B group was higher than that in A group. The frequence of phlebitis was significantly higher in group B than group A (P
